联环药业：LH-1801项目预计在未来相当一段时间内不会对公司营收和经营业绩产生重大影响

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced an abnormal fluctuation in its stock trading, with a cumulative price increase deviation of over 20% in three consecutive trading days [1] - The LH-1801 project is currently in the research and development stage and is not expected to have a significant impact on the company's revenue and operating performance in the foreseeable future [1]